CONCISE REVIEW

Human endothelial colony-forming cells in regenerative therapy: A systematic review of controlled preclinical animal studies

Gary Liao1,2 | Katina Zheng2 | Risa Shorr3 | David S. Allan1,2

1Clinical Epidemiology and Regenerative Medicine Programs, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada
2Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada
3Information Services, The Ottawa Hospital, Ottawa, Ontario, Canada

Correspondence
David S. Allan, MD, FRCPC, The Ottawa Hospital, 501 Smyth Road, Box 704, Ottawa, ON K1H 8L6, Canada.
Email: daallan@ohri.ca

Abstract
Endothelial colony-forming cells (ECFCs) hold significant promise as candidates for regenerative therapy of vascular injury. Existing studies remain largely preclinical and exhibit marked design heterogeneity. A systematic review of controlled preclinical trials of human ECFCs is needed to guide future study design and to accelerate clinical translation. A systematic search of Medline and EMBASE on 1 April 2019 returned 3131 unique entries of which 66 fulfilled the inclusion criteria. Most studies used ECFCs derived from umbilical cord or adult peripheral blood. Studies used genetically modified immunodeficient mice (n = 52) and/or rats (n = 16). ECFC phenotypes were inconsistently characterized. While >90% of studies used CD31+ and CD45−, CD14− was demonstrated in 73% of studies, CD146+ in 42%, and CD10+ in 35%. Most disease models invoked ischemia. Peripheral vascular ischemia (n = 29), central nervous system ischemia (n = 14), connective tissue injury (n = 10), and cardiovascular ischemia and reperfusion injury (n = 7) were studied most commonly. Studies showed predominantly positive results; only 13 studies reported ≥1 outcome with null results, three reported only null results, and one reported harm. Quality assessment with SYRCLE revealed potential sources of bias in most studies. Preclinical ECFC studies are associated with benefit across several ischemic conditions in animal models, although combining results is limited by marked heterogeneity in study design. In particular, characterization of ECFCs varied and aspects of reporting introduced risk of bias in most studies. More studies with greater focus on standardized cell characterization and consistency of the disease model are needed.

KEYWORDS
controlled studies, ECFCs, preclinical, regenerative medicine, systematic review

1 INTRODUCTION

Endothelial colony forming cells (ECFCs) have with robust proliferative potential and self-renewal capacity, making them of particular interest for cell-based regenerative therapy of diseases with a vascular etiology.1,2 Animal models of ischemic peripheral vascular injury, cerebral ischemia, and ischemic retinopathy have been used to study ECFC-based treatments.3 ECFCs have been researched under various...
additional monikers, including but not limited to, "blood outgrowth endothelial cells" and "late outgrowth endothelial cells."\textsuperscript{4-7} Ambiguity, however, persists regarding the reported characterization of ECFCs used in some preclinical studies. More recent stringent criteria proposed by Medina et al (henceforth referred to as the Medina Criteria) offer a more precise and a reproducible definition of cell type based on a profile of cell surface expression markers and allows for the comparison between studies and appropriate pooling of results from different studies to assess the efficacy of ECFC-based therapy.\textsuperscript{8} A systematic review of the literature is needed to evaluate preclinical studies using ECFCs in animal models of disease to assess cell characterization methods and other aspects of study design and treatment administration that are associated with potential benefit. This will accelerate the development of more definitive preclinical studies and will propel the field of ECFC therapy toward informative clinical trial development.

2 | METHODS

2.1 | Systematic search and study selection

A detailed description of the registered protocol for our systematic review is available on PROSPERO (Record ID: CRD42019140115) and was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement for reporting systematic reviews.\textsuperscript{9} In brief, a systematic search for keywords relating to vascular progenitors and ECFCs was conducted on Medline and EMBASE without limits on year or language of publication up to 1 April 2019. Our search was designed to capture a broad range of articles that used any type of endothelial progenitor cell to treat or repair end organ or organ system damage in preclinical animal models of disease. The title and abstract of each record were screened in duplicate using Covidence Systematic Review Software to identify publications with potential relevance. Conflicts were resolved by reaching consensus between two reviewers (G. L., K. Z.) and/or involving a third reviewer (D. S. A.). Initial (level 1) screening of selected studies was conducted using predetermined criteria and was aimed at excluding studies which lacked control groups, did not use a cell type that was closely or potentially related the definition of ECFC as outlined by the Medina Criteria,\textsuperscript{8} or did not study ECFCs in an animal model of disease (ie, excluded in vitro studies and studies where cells or cell-derived products were not administered to animals). Full-text eligibility determination (level 2 screening), was conducted by exporting all selected citations to EndNote X9 (Clarivate Analytics, Toronto, Canada), including full-text PDFs and their accompanying supplements. Full texts that could not be retrieved automatically were manually collected and uploaded. Full texts were assessed for inclusion and exclusion criterion in duplicate by two separate reviewers (G. L., K. Z.) and any conflicts were resolved by discussion and/or a third reviewer (D. S. A.). At this stage, criteria ensured that the cells used in the studies were of human origin and were characterized sufficiently to be considered ECFCs. Sufficient characterization specifically meant adequate documentation of cell surface marker expression using modified, or minimal, criteria from the aforementioned Medina Criteria (Figure 1). Sufficient reporting of ECFC characterization included information within the primary article, within a referenced protocol that included ECFC characterization, or within a previously published study that provided adequate reporting of ECFCs. All studies had to include adequate controls and report on at least one outcome related to the organ injury or function. More detail regarding the specific inclusion and exclusion criteria can be found in the published protocol on PROSPERO.

2.2 | Determining risk of bias, data extraction, and data analysis

Risk of bias analysis of study methods and reporting was conducted in duplicate using SYRCLE which is derived from the Cochrane risk of bias tool and has been adapted to preclinical animal trials.\textsuperscript{10} Data extraction was done in duplicate and collected using Airtable (Airtable, San Francisco, California), and included study characteristics, including

Full Medina Criteria

| All: CD31+, CD105+, and CD146+ |
| Both: CD45− and CD14− |

Modified Medina Criteria

| At least one: CD31+, CD105+, CD146+ |
| None: CD31−, CD105−, CD146− |
| At least one: CD45−, CD14− |
| Neither: CD45+, CD14+ |

Both Criteria Require

Intrinsic tube forming capacity in vitro and in vivo

FIGURE 1  Complete Medina Criteria compared to the modified Medina Criteria. Figure adapted from the Medina et al study.\textsuperscript{8}
the species of animals used, specifics of the disease model studied, cell characterization information, reported outcomes, and whether or not benefit was reported. Data concerning the Medina criteria for ECFC characterization was extracted and studies were categorized accordingly.

3 | RESULTS

3.1 | Characteristics of included studies

A total of 3142 studies were identified in our systematic search. Eleven duplicates were automatically removed, and 2689 records were excluded after screening for potential relevance by title and abstract. A total 442 full texts were assessed for eligibility, and 376 were excluded: 130 records were abstracts only, 116 records used cells that were not human, 46 records did not provide details of cell characterization, 20 were recognized as additional duplicate publications, 18 publications were not available in English, 15 publications did not study ECFCs, 13 studies did not administer cell products with therapeutic intent, and 5 studies administered cells to humans. A total of 66 studies were included in our final review and analysis (Figure 2). All studies that were included were published in 2009 or later. Publication rates peaked in 2014 with 10 studies. The largest number of studies were published by investigators from France, Korea, China, and Canada (Supporting Information 1).

All included studies used either mice or rats in their animal models (Table 1). Multiple genetic strains of mice were used, with the most common being various immunodeficient subtypes (BALB/c, NOD-SCID) followed by C57BL/6J. Rats were predominantly Sprague Dawley. No other species of animals were used. ECFCs were derived predominantly from human umbilical cord blood (n = 55; 83%) while remaining studies expanded ECFCs from peripheral blood (n = 11; 17%) of healthy adult volunteers. One study used ECFCs collected from human placenta.

Most (n = 59, 89%) studies administered ECFCs while 12 studies also included experiments with derivative products such as extracellular vesicles (ie, exosomes or microvesicles), and/or conditioned media (Table 1). The majority of studies administered cells and/or derivative products via intravenous injection (n = 32; 48%) or intramuscularly (n = 15; 23%). A single study explored topical

TABLE 1 Study characteristics

| Study characteristic | # of studies, n (%) (total n = 66) |
|----------------------|-----------------------------------|
| Animal species used  |                                   |
| Mouse                | 50 (76)                           |
| Rat                  | 14 (21)                           |
| Both                 | 2 (3)                             |
| ECFC source          |                                   |
| Umbilical cord       | 55 (83)                           |
| Peripheral           | 11 (17)                           |
| Placental            | 1 (2)                             |
| Interventions studied|                                   |
| ECFC (cells only)    | 54 (82)                           |
| ECFC conditioned media | 5 (8)                       |
| ECFC extracellular vesicles | 7 (11)               |
| Route of administration|                                 |
| Systemic—33 (50)     |                                   |
| Intravenous or arterial | 33 (50)           |
| Local—36 (54)*       |                                   |
| Intramuscular        | 15 (23)                           |
| Intramyocardial      | 4 (6)                             |
| Intravitreal         | 4 (6)                             |
| Intraperitoneal      | 3 (5)                             |
| With transplanted tissue | 3 (5)                     |
| Otherb               | 12 (18)                           |

Note: In some cases, studies reported more than one category of characteristic listed below, and the total numbers may add up to more than 100%.

*Three articles assess local administration also assessed systemic administration.

bOther includes: intracavernous (two studies), retro-orbital injection (two studies), subcutaneous (two studies) and intra-aortal, intradermal, intrathecal, intraventricular, subcapsular injection, and topical (one study each).

Abbreviation: ECFC, endothelial colony-forming cell.
application as a method of delivering either cells and/or cell-derived products.31

3.2 | Risk of bias

The risk of potential bias in the studies included in our analysis was assessed with the SYRCLE tool and reveals an overall high or unclear risk of bias. Most studies controlled for baseline characteristics between experimental groups well and most studies were not affected by "other sources of bias" such as nonpublic funding sources and conflicts of interest. However, many studies did not describe allocation concealment, blinding of investigators to the intervention, and random outcome assessment (see Table 2). Selective outcome reporting was unclear across the board as there were no readily available a priori protocols that allowed for the assessment of whether or not the data and results reported were congruent with the intention of the study at its inception.

3.3 | Cell and cell product characterization

As part of the inclusion criteria, all studies fulfilled our modified Medina criteria (Figure 1). Reporting of cell surface markers was heterogeneous (Figure 3). In general, a large majority of studies reported CD31 as a positive marker (n = 61; 92%) and CD45 as a negative marker (n = 62; 94%). Absence of CD14 was reported in most (n = 48; 73%) studies as a negative marker. Positive surface expression of CD105 and CD146 were reported in 35% and 42% of studies, respectively. Only 11 studies (17%) met the complete Medina criteria18,19,29,33-40 with just four studies (6%)19,29,34,38 reporting complete characterization information within the primary article (Supporting Information 2).

3.4 | Organ system injury models and outcome reporting

Most studies (n = 53; 80%) assessed more than one outcome. A total of 63 studies (95%) reported benefit in at least one outcome and only 13 (20%) reported no benefit in at least one outcome. Only beneficial outcomes were reported in 53 studies (80%) while only no benefits were reported in only three studies (4.5%).20,41,42 Only a single study reported an outcome with harm (Table 3).43 Analysis of outcomes by organ system did not reveal any organ system for which ECFCs did not demonstrate benefit within this sample of studies. Refer to the table (Supporting Information 2) which outlines specific study characteristics and outcomes in more detail.

The most commonly modeled organ dysfunction was peripheral vascular ischemia (n = 29, 44%) and central nervous system injury (n = 14, 21%) (Table 3). Some organ injury categories included multiple types of organ dysfunction, while other categories were more homogenous in the induction of organ dysfunction. In particular, hind limb ischemia (n = 23),16-18,21,22,32,33,36,39,44-57 cerebral ischemia (n = 7),12,37,58-62 and acute renal injury (n = 6)11,23,26,27,30,63 studies represent the three most common models of organ dysfunction (Table 4). Studies using hind limb ischemia as a model most often assessed revascularization by monitoring limb perfusion using ultrasound and reporting the ratio as a comparison with the unaffected limb.

Some studies also assessed histological and biochemical outcomes after sacrificing the animals. For cerebral ischemia, functional outcomes were most commonly assessed along with histological evidence of vascularization. Acute kidney injury models predominantly reported biochemical markers of kidney function and histology of renal tissue. The chief outcomes reported in these studies and whether benefit was observed is summarized in Table 4.

![FIGURE 3](Image)

**TABLE 2** Risk of bias using criteria from the SYRCLE risk of bias tool

| Risk domain                  | Low | Unclear | High |
|------------------------------|-----|---------|------|
| Sequence generation          | 3%  | 33%     | 64%  |
| Baseline characteristics     | 77% | 18%     | 5%   |
| Allocation concealment       | 3%  | 2%      | 95%  |
| Random housing               | 0%  | 33%     | 67%  |
| Blinding (intervention)      | 3%  | 2%      | 95%  |
| Random outcome assessment    | 12% | 11%     | 77%  |
| Blinding (outcome assessment)| 42% | 5%      | 53%  |
| Incomplete outcome data      | 39% | 59%     | 2%   |
| Selective outcome reporting  | 0%  | 100%    | 0%   |
| Other sources of bias        | 86% | 9%      | 5%   |
| Overall risk of bias         | 0%  | 30%     | 70%  |

The highest (bold italics), second highest (bold), and lowest (italics) proportion of studies categorized as low, unclear, or high risk of bias for each criterion is listed in the table along with the overall risk of bias.
studies of hind limb ischemia, improved limb perfusion was reported in 22 of 23 studies with improved muscle injury scores in all five studies reporting this outcome. Capillary density was improved in 10 of 11 studies. Regarding studies of cerebral ischemia (n = 7), all six studies reporting on neurological scores and/or results of the maze test reported improvement with ECFCs, the only study reporting somatosensory function demonstrated improvement, and five of six studies reporting neuronal histology described beneficial changes. All six studies of acute kidney injury reported improved creatinine and blood urea nitrogen levels and favorable histological changes.

### DISCUSSION

Our systematic review of the literature provides useful insight into several aspects of controlled preclinical trials involving ECFCs. It highlights that research regarding the potential clinical application of this endothelial progenitor is still evolving rapidly, with most preclinical research emerging within the last decade or less. Additionally, our analysis confirms the relevance of ECFCs in ischemic models of tissue injury and identifies robust cell characterization as an important aspect of future ECFC studies. Heterogeneity in reporting of ECFC characterization limits the ability to pool results from different studies; however, the use of a modified Medina criteria provides a basis for defining the minimal criteria needed for combining studies. While potential risk of bias was observed and publication bias was likely present due to the preclinical nature of studies, positive outcomes were reported in a large proportion of studies across a broad range of organ systems, providing encouragement that ECFC-based therapy holds promise in the treatment of vascular ischemia and other organ systems. Moreover, use of standardized criteria for ECFC characterization will allow greater confidence regarding efficacy of ECFC therapy in various injury models and will accelerate the translation of preclinical research to clinical trials of ECFC therapy. Future studies should embrace methods that reduce the potential for biased reporting, such as allocation concealment, randomization, and blinding of outcome assessors. Moreover, use of standardized criteria for ECFC characterization will allow greater confidence regarding efficacy of ECFC therapy in various injury models and will accelerate the translation of preclinical research to clinical trials of ECFC therapy. ECFCs defined by the Medina 2017 consensus statement should be strongly considered as a unified standard as it relies on robust markers of surface expression which can be easily assessed by flow cytometry and a relatively simple functional assay of
tube forming capacity.\textsuperscript{8} Additionally, beyond assessing intrinsic tube forming capacity, future studies should also consider characterizing ECFCs using a potency assays to further aid standardization and reproducibility.

Although our review clearly demonstrates the relevance of ECFCs in ischemic injury as a whole, we are unable to offer conclusions regarding which disease models should be prioritized for future trials. A significant proportion of studies used hind limb ischemia in their experimental model, this may reflect the utility of this model in assessing revascularization and functional recovery. Given the beneficial results in other models of ischemia injury, the applicability to clinical trials may not be restricted to peripheral vascular disease as much as acute ischemic injury more generally. Conversely, the surgical and/or mechanical induction of acute ischemic injury in the animal models may not reflect the clinical reality in most cases where the surrounding tissues and repair responses may also be implicated in any underlying disease process, particularly atherosclerotic ischemic injury that underpins most cerebral and cardiovascular ischemic events. Future preclinical trials should aim to explore the potential uses of ECFC in a greater variety of disease models that accurately reflect clinical scenarios to aid in the prioritization of indications for clinical trials.

The translation of preclinical research to clinical studies will also require greater attention to safety assessments which were largely lacking from the studies identified in our analysis. Cell-based therapies introduce the potential for off-target or unintended effects in other tissues and organs that need to be considered. Although the longitudinal intrinsic proliferative capacity of ECFCs in vivo has been assessed and has demonstrated relative safety in a few reports,\textsuperscript{66,67} it remains reasonable to consider their ability to cause potential harm\textsuperscript{68} related to persistence after repair is complete. The majority of preclinical studies in this review reported only the outcomes related to the injured organ system without specific consideration for other systems and the limited follow-up for outcome reporting in these studies precludes the ability to assess for potential long-term complications in the animals. Clarifying and anticipating these potential complications may further facilitate transition toward clinical trials.

Methodological issues related to the isolation, culture, and expansion of ECFCs are also potential barriers to translation that must be considered. Ideally, for early phase I/II clinical trials, ECFCs would be autologous, isolated from peripheral circulation, and expanded ex vivo in culture conditions that are compatible for human use. This would maximize safety to participants and minimize the presence of immunogenicity as a potential confounder. Protocols for successfully isolating and expanding ECFCs from unmodified whole blood using human platelet lysate in place of fetal bovine serum for culture supplementation have been described previously.\textsuperscript{69} Furthermore, there is some evidence that ECFCs cultured with human platelet lysates may also exhibit greater vasculogenic capacity.\textsuperscript{70} However, these protocols will likely require further optimization and adaptation to ensure the cells produced conform with Good Manufacturing Practices for cell therapies required for clinical trials within various jurisdictions.\textsuperscript{71} Future studies should aim to expand their ECFCs in human compatible cultures whenever possible to mimic the eventual intervention to be administered in clinical trials. Use of allogeneic cells such as those expanded from human umbilical cord blood may also be explored in human leukocyte antigen matched donor-recipient pairs and/or with immunosuppression.\textsuperscript{72}

There are limitations of our review worth mentioning. Our initial literature search was broad to capture as many relevant articles as possible; however, it is possible that some published preclinical studies were not captured. Furthermore, our search and inclusion criteria were limited to articles published in English. It is clear even within our review that active research in this field is being conducted at an international level increasing the likelihood that there may be articles published in sources that were not captured in our search. It is also possible that we included in our analysis studies that did not truly use a cell phenotype that can be classified as an ECFC although we embraced criteria based on the consensus definition reported by Medina et al\textsuperscript{8} and we included studies which reported on ECFC characterization either within the primary article or within referenced protocols or previous articles. By including studies that characterized ECFCs based on less stringent criteria than outlined by Medina 2017,\textsuperscript{8} we introduced a degree of heterogeneity in cell characterization across the studies. As more studies embrace the full complement of criteria outlined by Medina et al, future analyses can focus only on studies that report the full set of established criteria.

\section*{CONCLUSION}

We conducted a systematic review which reveals that the body of evidence supporting the use of ECFCs as a potential cell-based regenerative therapy continues to grow rapidly with suggested benefit particularly in ischemic injuries across a range of organ systems including peripheral arterial occlusion, cerebral ischemia, and acute renal injury. However, the presence of potential reporting bias was observed and heterogeneity in cell-product characterization existed in the studies we identified in our analysis which precluded the ability to combine studies for meta-analysis. We suggest that future preclinical studies involving ECFCs be conducted with greater rigor to enable more rapid transition to clinical trials. This may be achieved by implementing standardized ECFC characterization based on the full Medina criteria which will reduce confusion in the literature, by incorporating methods to minimize sources of bias, by assessing for adverse outcomes in other tissue and at longer follow-up time points, and by exploring a greater variety of disease models that are clinically relevant.

\section*{ACKNOWLEDGMENT}

We acknowledge financial support for student stipend from the Faculty of Medicine, University of Ottawa (G. L.).

\section*{CONFLICT OF INTEREST}

D.S.A. declared consultant/advisory role for Canadian Blood Services. All the other authors declared no potential conflicts of interest.
AUTHOR CONTRIBUTIONS
G.L., K.Z.: conception and design, collection and assembly of data, data analysis and interpretation, manuscript writing and editing, approval of final manuscript; R.S.: administrative support, collection and assembly of data, approval of final manuscript; D.S.A.: conception and design, financial support, administrative support, manuscript writing and editing, approval of final manuscript.

DATA AVAILABILITY STATEMENT
Data sharing is not applicable to this article as no new data were created or analyzed in this study.

ORCID
Katina Zheng https://orcid.org/0000-0003-3004-156X
David S. Allan https://orcid.org/0000-0003-3261-8289

REFERENCES
1. Yoder MC, Mead LE, Prater D, et al. Redefining endothelial progenitor cells via clonal analysis and hematopoietic stem/progenitor cell principals. Blood. 2007;109(5):1801-1809. https://doi.org/10.1182/blood-2006-08-043471
2. O'Neill CL, McLoughlin KJ, Chambers SEJ, Guduric-Fuchs J, Stitt AW, Medina RJ. The vasoprotective potential of endothelial colony forming cells: a journey through pre-clinical studies. Front Med. 2018;5(273). https://doi.org/10.3389/fmed.2018.00273
3. Paschalaki KE, Randi AM. Recent advances in endothelial colony forming cells toward their use in clinical translation. Front Med. 2018;5(293). https://doi.org/10.3389/fmed.2018.00295
4. Ingram DA, Mead LE, Tanaka H, et al. Identification of a novel hierarchy of endothelial progenitor cells using human peripheral and umbilical cord blood. Blood. 2004;104(9):2752-2760. https://doi.org/10.1182/blood-2004-04-1396
5. Hur J, Yoon CH, Kim HS, et al. Characterization of two types of endothelial progenitor cells and their different contributions to neovascularogenesis. Arterioscler Thromb Vasc Biol. 2004;24(2):288-293. https://doi.org/10.1161/01.ATV.0000114236.77009.06
6. Starke RD, Paschalaki KE, Dyer CEF, et al. Cellular and molecular basis of von Willebrand disease: studies on blood outgrowth endothelial cells. Blood. 2013;121(4):2773-2784. https://doi.org/10.1182/blood-2012-06-435727
7. Wang SH, Lin SJ, Chen YH, et al. Late outgrowth endothelial cells derived from Wharton jelly in human umbilical cord reduce neointimal formation after vascular injury: involvement of pigment epithelium-derived factor. Arterioscler Thromb Vasc Biol. 2009;29(6):816-822. https://doi.org/10.1161/ATVBAHA.109.184739
8. Medina RJ, Barber CL, Sabatier F, et al. Endothelial progenitors: a consensus statement on nomenclature. STEM CELLS TRANSITIONAL MEDICINE. 2017;6(5):1316-1320. https://doi.org/10.1002/sctm.16-0360
9. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009;339:b2700. https://doi.org/10.1136/bmj.b2700
10. Hooijmans CR, Rovers MM, de Vries RBM, Leenaars M, Ritskes-Hoitinga M, Langendam MW. SyRCLE's risk of bias tool for animal studies. BMC Med Res Methodol. 2014;14(1):43. https://doi.org/10.1186/1471-2288-14-43
11. Cantaluppi V, Gatti S, Medica D, et al. Microvesicles derived from endothelial progenitor cells protect the kidney from ischemia-reperfusion injury by microRNA-dependent reprogramming of resident renal cells. Kidney Int. 2012;82(4):412-427. https://doi.org/10.1038/ki.2012.105
12. Choi SA, Chong S, Kwak PA, et al. Impaired functional recovery of endothelial colony-forming cells from moyamoya disease in a chronic cerebral hypoperfusion rat model. J Neurosurg Pediatr. 2018;23(2):204-213.
13. Zigdon-Giladi H, Elimelech R, Michaelli-Geller G, Rudich U, Machtet EE. Safety profile and long-term engraftment of human CD31+ blood progenitors in bone tissue engineering. Cytoterapy. 2017;19(7):895-908. https://doi.org/10.1016/j.jcyt.2017.03.079
14. Coppens V, Heremans Y, Leuckx G, et al. Human blood outgrowth endothelial cells improve islet survival and function when co-transplanted in a mouse model of diabetes. Diabetologia. 2013;56(2):392-390. https://doi.org/10.1007/s00125-012-2754-3
15. Coppens V, Heremans Y, Leuckx G, et al. Reversal of hyperglycemia in diabetic mice by a marginal islet mass together with human blood outgrowth endothelial cells is independent of the delivery technique and blood clot-induced processes. Islets. 2013;5(5):196-200. https://doi.org/10.4161/isl.26778
16. Cubbon RM, Yuldasheva NY, Viswambharan H, et al. Restoring Akt1 activity in outgrowth endothelial cells from South Asian men rescues vascular reparative potential. STEM CELLS. 2014;32(10):2714-2723. https://doi.org/10.1002/stem.1766
17. Joo HJ, Seo HR, Jeong HE, et al. Smooth muscle progenitor cells from peripheral blood promote the neovascularization of endothelial colony-forming cells. Biochem Biophys Res Commun. 2014;449(4):405-411. https://doi.org/10.1016/j.bbrc.2014.05.061
18. Leicht SF, Schwarz TM, Hermann PC, Seissler J, Aicher A, Heeschen C. Adiponectin pretreatment counteracts the detrimental effect of a diabetic environment on endothelial progenitors. Diabetes. 2011;60(2):652-661. https://doi.org/10.2337/db10-0240
19. Medina RJ, O'Neill CL, Humphreys MW, Gardiner TA, Stitt AW. Outgrowth endothelial cells: characterization and their potential for reversing ischemic retinopathy. Invest Ophthalmol Vis Sci. 2010;51(11):5906-5913. https://doi.org/10.1167/iovs.09-4951
20. Ormiston ML, Deng Y, Stewart DJ, Courtman DW. Innate immunity in the therapeutic actions of endothelial progenitor cells in pulmonary hypertension. Am J Respir Cell Mol Biol. 2010;43(5):546-554.
21. Rignault-Clerc S, Biehmann C, Delodder F, et al. Functional late outgrowth endothelial progenitors isolated from peripheral blood of burned patients. Burns. 2013;39(4):694-704. https://doi.org/10.1016/j.burns.2012.09.027
22. Patel J, Wong HY, Wang W, et al. Self-renewal and high proliferative colony forming capacity of late-outgrowth endothelial progenitors is regulated by cyclin-dependent kinase inhibitors driven by notch signaling. STEM CELLS. 2016;34(4):902-912. https://doi.org/10.1002/stem.2262
23. Burger D, Vinas JL, Abkari S, et al. Human endothelial colony-forming cells protect against acute kidney injury: role of exosomes. Am J Pathol. 2015;185(8):2309-2323. https://doi.org/10.1016/j.ajpath.2015.04.010
24. Gao W, Li F, Liu L, et al. Endothelial colony-forming cell-derived exosomes restore blood-brain barrier continuity in mice subjected to traumatic brain injury. Exp Neurol. 2018;307:99-108. https://doi.org/10.1016/j.expneurol.2018.06.001
25. Li X, Jiang C, Zhao J. Human endothelial progenitor cells-derived exosomes accelerate cutaneous wound healing in diabetic rats by promoting endothelial function. J Diabetes Complications. 2016;30(6):986-992. https://doi.org/10.1016/j.jdiacomp.2016.05.009
26. Vinas JL, Burger D, Zimpelmann J, et al. Transfer of microRNA-486-5p from human endothelial colony forming cell-derived exosomes reduces ischemic kidney injury. Kidney Int. 2016;90(6):1238-1250. https://doi.org/10.1016/j.kint.2016.07.015
27. Vinas JL, Spence M, Gutsol A, et al. Receptor-ligand interaction mediates targeting of endothelial colony forming cell-derived exosomes to the kidney after ischemic injury. Sci Rep. 2018;8(1):16320. https://doi.org/10.1038/s41598-018-34557-7
28. Tu TC, Yamashita T, Kato T, et al. Microvesicles derived from Alde- low EPCs support the wound healing capacity of AT-MSCs. Biochem Biophys Res Commun. 2016;477(1):68-75. https://doi.org/10.1016/j.bbrc.2016.06.022

29. Alphonse RS, Vadel A, Fung M, et al. Existence, functional impairment, and lung repair potential of endothelial colony-forming cells in oxygen-induced arrested alveolar growth. Circulation. 2014;129(21):2144-2157. https://doi.org/10.1161/CIRCULATIONAHA.114.009124

30. Collett JA, Mehrotra P, Crane A, Shelley WC, Yoder MC, Basile DP. Endothelial colony-forming cells ameliorate endothelial dysfunction via secreted factors following ischemia-reperfusion injury. Am J Physiol Ren Physiol. 2017;312(5):F897-F907. https://doi.org/10.1152/ajprenal.00643.2016

31. Lee MJ, Kim J, Lee KI, Shin JM, Chae JI, Chung HM. Enhancement of wound healing by secretory factors of endothelial precursor cells derived from human embryonic stem cells. Cytotherapy. 2011;13(2):165-178. https://doi.org/10.3109/14636540.2010.512632

32. Odent Grigorescu G, Preda MB, Rudu E, et al. Combinatorial approach for improving the outcome of angiogenic therapy in ischemic tissues. Biomaterials. 2015:60:72-81. https://doi.org/10.1016/j.biomaterials.2015.05.002

33. Zhao L, Liu X, Zeng P, Chen K, Mo Z. Synergistic effect of umbilical cord mesenchymal stem cells and endothelial colony-forming cells on angiogenesis in diabetic mice. J Biomater Tissue Eng. 2018;8(6):837-844. https://doi.org/10.1166/jbte.2018.1822

34. Girard-Bock C, de Araujo CC, Bertagnolli M, et al. Endothelial colony-forming cell therapy for heart morphological changes after neonatal high oxygen exposure in rats, a model of complications of prematurity. Physiol Rep. 2018;6(22):e13922. https://doi.org/10.14814/phy2.13922

35. Huang XT, Zhang YQ, Li SJ, et al. Intracerebroventricular transplantation of ex vivo expanded endothelial colony-forming cells restores blood-brain barrier integrity and promotes angiogenesis of mice with traumatic brain injury. J Neurotrauma. 2013;30(24):2080-2088. https://doi.org/10.1089/neu.2013.2996

36. Lee SH, Lee JH, Asahara T, et al. Genistein promotes endothelial colony-forming cell (ECFC) bioactivities and cardiac regeneration in myocardial infarction. PLoS One. 2014;9(5):e96155. https://doi.org/10.1371/journal.pone.0096155

37. Bouvard C, Gafou b, Dizier B, et al. alpha6-integrin subunit plays a major role in the proangiogenic properties of endothelial progenitor cells. Arterioscler Thromb Vasc Biol. 2010;30(8):1569-1575. https://doi.org/10.1161/ATVBAHA.110.209163

38. d’Audigier C, Susen S, Blandinieres A, et al. Egf1 represses the vasculogenic potential of human endothelial progenitor cells. Stem Cell Rev. 2018;14(1):82-91. https://doi.org/10.1007/s12928-017-0777-8

39. Flex A, Biscetti F, Iachinomoto MG, et al. Human cord blood endothelial progenitors promote post-ischemic angiogenesis in immunocompetent mouse model. Thromb Res. 2016;141:106-111. https://doi.org/10.1016/j.thromres.2016.03.012

40. Heo SC, Kwon YW, Jang IH, et al. WKYMVM-induced activation of formyl peptide receptor 2 stimulates ischemic neovascularization by promoting homing of endothelial colony-forming cells. Stem Cells. 2014;32(3):779-790. https://doi.org/10.1002/stem.1578

41. Kang KT, Lin RZ, Kuppermann D, Melero-Martin JM, Bischoff J. Endothelial colony forming cells and mesenchymal progenitor cells form blood vessels and increase blood flow in ischemic muscle. Sci Rep. 2017;7(1):770. https://doi.org/10.1038/s41598-017-0009-1

42. Lee JH, Lee SH, Choi SH, Asahara T, Kwon SM. The sulfated polysaccharide fucoidan rescues senescence of endothelial colony-forming cells for ischemic repair. Stem Cells. 2015;33(6):1939-1951. https://doi.org/10.1002/stem.1573

43. Lee JH, Lee SH, Yoo SY, Asahara T, Kwon SM. CD34 hybrid cells promote endothelial colony-forming cell bioactivity and therapeutic potential for ischemic diseases. Arterioscler Thromb Vasc Biol. 2013;33(7):1622-1634. https://doi.org/10.1161/ATVBAHA.112.301052

44. Mena HA, Lokajczyk A, Dizier B, et al. Acidic preconditioning improves the proangiogenic responses of endothelial colony forming cells. Angiogenesis. 2014;17(4):687-697. https://doi.org/10.1007/s10456-014-9434-5

45. Palli CG, Vulesevic B, Frainseau S, et al. Trichostatin a enhances vascular repair by injected human endothelial progenitors through increasing the expression of TAL1-dependent genes. Cell Stem Cell. 2014;14(5):644-657. https://doi.org/10.1016/j.stem.2014.03.003

46. Poltevin S, Cussac D, Leroyer AS, et al. Sphingosine kinase 1 expression by endothelial colony-forming cells has a critical role in their revascularization activity. Cardiovasc Res. 2014;103(1):121-130. https://doi.org/10.1093/cvr/cvu104

47. Rossi E, Poirault-Chassac S, Bieche I, et al. Human endothelial colony forming cells express intracellular CD133 that modulates their vasculogenic properties. Stem Cell Rev. 2019;15:16.

48. Sarlon G, Zemani F, David L, et al. Therapeutic effect of fucoidan-stimulated endothelial colony-forming cells in peripheral ischemia. J Thromb Haemost. 2012;10(1):38-48. https://doi.org/10.1111/j.1538-7836.2011.04554.x

49. Shen WC, Liang CJ, Wu VC, et al. Endothelial progenitor cells derived from Wharton’s jelly of the umbilical cord reduces ischemia-induced hind limb injury in diabetic mice by inducing HIF-1alpha/IL-8 expression. Stem Cells Dev. 2013;22(9):1408-1418. https://doi.org/10.1089/scd.2012.0445

50. Bennis Y, Sarlon-Bartoli G, Guillet B, et al. Priming of late endothelial progenitor cells with erythropoietin before transplantation requires the CD131 receptor subunit and enhances their angiogenic potential. J Thromb Haemost. 2012;10(9):1914-1928. https://doi.org/10.1111/j.1538-7836.2012.04835.x

51. Garrigue P, Hache G, Bennis Y, et al. Erythropoietin pretreatment of transplanted endothelial colony-forming cells enhances recovery in a cerebral ischemia model by increasing their homing ability: a SPECT/CT study. J Nucl Med. 2016;57(11):1798-1804.
59. Geng J, Wang L, Qu M, et al. Endothelial progenitor cells transplantation attenuated blood-brain barrier damage after ischemia in diabetic mice via HIF-1alpha. Stem Cell Res Ther. 2017;8(1):163. https://doi.org/10.1186/s13287-017-0605-3

60. Moubarik C, Guillet B, Youssef B, et al. Transplanted late outgrowth endothelial progenitor cells as cell therapy product for stroke. Stem Cell Rev. 2011;7(1):208-220. https://doi.org/10.1007/s12015-010-9157-y

61. Nih LR, Deroide N, Lere-Dean C, et al. Neuroblast survival depends on mature vascular network formation after mouse stroke: role of endothelial and smooth muscle progenitor cell co-administration. Eur J Neurosci. 2012;35(8):1208-1217. https://doi.org/10.1111/j.1460-9568.2012.08041.x

62. Pellegrini L, Bennis Y, Guillet B, et al. Therapeutic benefit of a combined strategy using erythropoietin and endothelial progenitor cells after transient focal cerebral ischemia in rats. Neurol Res. 2013;35(9):937-947. https://doi.org/10.1179/1743132813Y.0000000235

63. Liang CJ, Shen WC, Chang FB, et al. Endothelial progenitor cells derived from Wharton’s jelly of human umbilical cord attenuate ischemic acute kidney injury by increasing vascularization and decreasing apoptosis, inflammation, and fibrosis. Cell Transpl. 2015;24(7):1363-1377. https://doi.org/10.3727/096368914X681720

64. Korevaar DA, Hooff L, Ter Riet G. Systematic reviews and meta-analyses of preclinical studies: publication bias in laboratory animal experiments. Lab Anim. 2011;45(4):225-230. https://doi.org/10.1258/la.2011.010121

65. Lowenstein PR, Castro MG. Uncertainty in the translation of preclinical experiments to clinical trials. Why do most phase III clinical trials fail? Curr Gene Ther. 2009;9(5):368-374. https://doi.org/10.2174/156652309789753392

66. Milbauer LC, Enenstein JA, Roney M, et al. Blood outgrowth endothelial cell migration and trapping in vivo: a window into gene therapy. Transl Res. 2009;153(4):179-189. https://doi.org/10.1016/j.trsl.2008.12.009

67. Lin Y, Chang L, Solovey A, Healey JF, Lollar P, Hebbel RP. Use of blood outgrowth endothelial cells for gene therapy for hemophilia A. Blood. 2002;99(2):457-462. https://doi.org/10.1182/blood.V99.2.457

68. Volarevic V, Markovic BS, Gazdic M, et al. Ethical and safety issues of stem cell-based therapy. Int J Med Sci. 2018;15(1):36-45. https://doi.org/10.7150/ijms.21666

69. Reinisch A, Hofmann NA, Obenauf AC, et al. Humanized large-scale expanded endothelial colony-forming cells function in vitro and in vivo. Blood. 2009;113(26):6716-6725. https://doi.org/10.1182/blood-2008-09-181362

70. Kim H, Prasain N, Vemula S, et al. Human platelet lysate improves human cord blood derived ECFC survival and vasculogenesis in three dimensional (3D) collagen matrices. Microvasc Res. 2015;101:72-81. https://doi.org/10.1016/j.mvr.2015.06.006

71. Bedford P, Jy J, Collins L, Keizer S. Considering cell therapy product "good manufacturing practice" status. Front Med. 2018;5:118. https://doi.org/10.3389/fmed.2018.00118

72. Abrahimi P, Chang WG, Kluger MS, et al. Efficient gene disruption in cultured primary human endothelial cells by CRISPR/Cas9. Circ Res. 2015;117(2):121-128. https://doi.org/10.1161/CIRCRESAHA.117.306290

SUPPORTING INFORMATION

Additional supporting information may be found online in the Supporting Information section at the end of this article.

How to cite this article: Liao G, Zheng K, Shorr R, Allan DS. Human endothelial colony-forming cells in regenerative therapy: A systematic review of controlled preclinical animal studies. STEM CELLS Transl Med. 2020;9:1344–1352. https://doi.org/10.1002/sctm.20-0141